Glycated haemoglobin and long-term mortality in patients with ST Elevation Myocardial Infarction

Backgrounds/Objectives We aimed at assessing the impact of increased HbA1c (≥6.5%) on 1-year mortality in consecutive patients with ST Elevation Myocardial Infarction (STEMI) submitted to primary percutaneous coronary intervention (PCI). Methods The study population comprises 1205 STEMI patients treated with primary PCI and consecutively admitted to our Center from 1 January 2004 to 31 December 2011. Results Two hundred and seventy-six patients with previously diagnosed diabetes (276/1205, 22.9%, Group A), 78 patients without previously known diabetes and HbA1c at least 6.5% (78/1205, 6.5%, Group B) and 851 patients without previously known diabetes and HbA1c less than 6.5% (851/1205, 70.1%, Group C). At Cox regression analysis, HbA1c at least 6.5% was not related to 1-year postdischarge mortality in patients with previously diagnosed diabetes nor in those without previously known diabetes. Kaplan-Meier survival curve analysis showed that patients in Group A exhibited the lowest survival rate, while patients in Group B (i.e. patients without previously known diabetes and with HbA1c ≥6.5%) showed a significant reduction in their survival rate since 6 months after discharge. Conclusion In a large series of STEMI patients submitted to primary PCI, HbA1c levels were not related with outcomes at multivariable analysis.